PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.58%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-14.34%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-20.40%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-19.61%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-20.61%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.76%
Share reduction more than 1.5x AXSM's 2.00%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.74%
Negative OCF growth while AXSM is at 8.04%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-26.42%
Negative FCF growth while AXSM is at 8.08%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91846.40%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-21838.35%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
2.60%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-1109485.80%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20425.82%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
78.21%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
41985.76%
10Y equity/share CAGR above 1.5x AXSM's 678.09%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
3459.24%
5Y equity/share CAGR above 1.5x AXSM's 678.09%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
143.15%
Below 50% of AXSM's 678.09%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Negative asset growth while AXSM invests at 21.46%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-29.04%
We have a declining book value while AXSM shows 33.07%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth drastically higher vs. AXSM's 3.07%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
12.93%
We expand SG&A while AXSM cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.